Download Citation
Article Source:
Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
Engesæter B,
Engebraaten O,
Flørenes VA,
Mælandsmo GM
(2012)
Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma.
PLOS ONE 7(9): e45492.
https://doi.org/10.1371/journal.pone.0045492